Condition: Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma · Sponsor: Ruijin Hospital
The study is being conducted to evaluate the efficacy, safety and tolerability of radiotherapy and chemotherapy, apatinib with camrelizumab in the neoadjuvant (prior to surgery) and adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.
This description comes directly from the study's public registry record.
Shu-Bei Wang, MD · +86-021-64370045 · wangshubei@163.com
Gang Cai, MD · +86-021-64370045 · cg11855@rjh.com.cn
Always discuss trial participation with your own doctor first.
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07026149